| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| The biotechnology landscape is experiencing significant developments, particularly with increased activity around IPOs and merger rumors, indicating heightened market interest. Regulatory approval processes and innovative drug trials are also prevalent, with a focus on emerging therapies and AI-driven drug development gaining traction. However, workforce reductions at certain firms and mixed sentiment surrounding stock performances pose challenges. The overall market sentiment remains cautiously optimistic, buoyed by new advancements and strategic acquisitions. The price action of Small Biotechnology (XBI) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at 0.3 is modestly bullish. The market sentiment at 0.3 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.XBI is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for Small Biotechnology sector is at 0.5, and the negative at -0.3 on 2026-01-13. The forces of Option Sentiment (1.5), Market Risk Appetite (0.9), Broad Market Trend (0.3), Sector Price Trend (0.3), and Price Level Sentiment (0) will drive up the price. The forces of Valuation Sentiment (-0.5), and Sentiment towards Fundamentals (-1) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XBI trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| XBI | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-13 | 1%(0.4%) | 123.86 | 59 | -0.06% | 0.08% | 0.3 | -0.08% | 0.7% | 0.3 | Wait | 50% | -1 | 7 |
| 2026-01-12 | 1%(0.4%) | 123.93 | 60 | -0.44% | -0.08% | 0.6 | 0% | 1% | 0.2 | Long | 65% | -1 | 0.6 |
| 2026-01-11 | 0%(0.4%) | 0.6 | 0% | 0.1 | -1 | -0.5 | |||||||
| 2026-01-10 | 0%(0.6%) | 0.6 | 0% | 0.1 | -1 | 4.5 | |||||||
| 2026-01-09 | 1%(0.6%) | 124.48 | 68 | 0.62% | -0.16% | 0.6 | 0% | 0.8% | 0.4 | Long | 65% | -1 | 3 |
| 2026-01-08 | 0%(0.4%) | 123.71 | 60 | -2.13% | -0.08% | 0.5 | 0.08% | 1.1% | 0.2 | Wait | 50% | -1 | 4.3 |
| 2026-01-07 | 0%(0.4%) | 126.4 | 96 | 3.53% | 0% | 0.7 | 0.33% | 1.8% | 0.1 | Wait | 50% | -1 | 3.8 |
| 2026-01-06 | 1%(0.7%) | 122.09 | 40 | 1.63% | -0.08% | -0.2 | 0% | 0.9% | 0.2 | Long | 65% | -1 | 1.4 |
| 2026-01-05 | 1%(0.7%) | 120.13 | 11 | -1.15% | 0% | -0.4 | -0.08% | 1% | 0.1 | Wait | 50% | -1 | 1.8 |
| 2026-01-04 | 1%(0.7%) | -0.2 | -0.05% | -0.3 | -1 | 7.5 | |||||||
| Wait is the preferred trading strategy with 50% chance of being right. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| Market News | ||
| 1 (8) TG Therapeutics Stock Climbs After The Bell: Here's Why TG Therapeutics releases its preliminary Q4 revenue estimates and provides an optimistic outlook for 2026. (https://www.benzinga.com/) Tue. Jan 13, 2026 | ||
| 2 (7) XTL Biopharmaceuticals To Acquire 85% Stake In NeuroNOS Ltd For $32.5 Mln XTL Biopharmaceuticals Ltd. (XTLB), a biopharmaceutical company, Tuesday announced that it has agreed to acquire 85 percent of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc. (https://www.rttnews.com/) Tue. Jan 13, 2026 | ||
| 3 (8) SciSparc To Buy IP Rights For Endoscopic Systems And Medical Cameras SciSparc Ltd. (SPRC), Tuesday announced a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE system, from Xylo Technologies Ltd. (https://www.rttnews.com/) Tue. Jan 13, 2026 | ||
| 4 (9) Beyond Air, Inc. Shares Surge 166% On NeuroNOS Transaction Beyond Air, Inc. (XAIR) jumped sharply on Tuesday, rising 165.41 percent, or $1.4490, as the market reacted to XTL Biopharmaceuticals' announcement that it agreed to acquire 85 percent of NeuroNOS Ltd. (https://www.rttnews.com/) Tue. Jan 13, 2026 | ||
| 5 (8) XTL Biopharmaceuticals Shares Surge 58% After NeuroNOS Acquisition Announcement XTL Biopharmaceuticals Ltd. (XTLB) jumped sharply on Tuesday, rising 58.13 percent, or $0.3970, to trade at $1.08, after the company announced a binding agreement to acquire an 85 percent stake in NeuroNOS Ltd. (https://www.rttnews.com/) Tue. Jan 13, 2026 | ||
| 6 (8) Why Moderna Stock Strength Is Only Beginning: Technical Analysis Moderna stock is now putting its foot on the accelerator in 2026—and the chart suggests that more gains are coming. (https://www.barrons.com/) Tue. Jan 13, 2026 | ||
| 7 (5) CORRECTED: Why Is Novavax Stock Soaring? Novavax Inc (NASDAQ:NVAX) shares are trading higher. Reports show a rise in respiratory illnesses across the United States. (https://www.benzinga.com/) Tue. Jan 13, 2026 | ||
| 8 (7) Why Is Vericel Stock Gaining Tuesday? Vericel Corporation (NASDAQ: VCEL) stock rose on Tuesday after announcing preliminary financial results for 2025. (https://www.benzinga.com/) Tue. Jan 13, 2026 | ||
| 9 (7) Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout Aclarion, Inc. (NASDAQ: ACON) closed a $10.4 million financing at $5.18/share, boosting balance sheet & extending cash runway to 2028. (https://www.benzinga.com/) Tue. Jan 13, 2026 | ||
| 10 (8) Proxima Raises $80 Million for AI Drug Discovery From DCVC, Nvidia Proxima, a biotech startup using artificial intelligence to design drugs that control protein interactions, raised $80 million in seed funding, which will help it collect better data and eventually develop potential drug candidates. (https://www.bloomberg.com/) Tue. Jan 13, 2026 | ||
| 11 (8) REGENXBIO Stock Hits New High On Duchenne Trial Data - Will 2026 Be A Transformative Year? Shares of REGENXBIO Inc. (RGNX) are up over 11% at $16.27 in premarket trading on Monday, following encouraging new long-term data for its Duchenne program and key catalysts lined up for this year. (https://www.rttnews.com/) Mon. Jan 12, 2026 | ||
| 12 (-7) Sarepta Falls After Gene Therapy Elevidys Misses Estimates Sarepta Therapeutics Inc. fell Monday after reporting its embattled gene therapy is expected to miss fourth-quarter sales estimates. (https://www.bloomberg.com/) Mon. Jan 12, 2026 | ||
| 13 (8) Beam Therapeutics Stock Surges: What's Driving The Sudden Jump? Beam Therapeutics shares are popping on Monday after the company laid out a series of pipeline updates and strategic priorities for 2026. (https://www.benzinga.com/) Mon. Jan 12, 2026 | ||
| 14 (-5) ‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News. Monday is the first day of J.P. Morgan’s annual healthcare investor conference. (https://www.barrons.com/) Mon. Jan 12, 2026 | ||
| 15 (-6) ‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News. Monday is the first day of J.P. Morgan’s annual healthcare investor conference. (https://www.barrons.com/) Mon. Jan 12, 2026 | ||
| 16 (7) 2 Biotech Stocks That Could Soar This Year And, if all goes well, over the next five years as well. (https://www.fool.com/) Mon. Jan 12, 2026 | ||
| 17 (-4) Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement. (https://www.benzinga.com/) Mon. Jan 12, 2026 | ||
| 18 (8) Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4. (https://www.benzinga.com/) Mon. Jan 12, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA